Evidence map›Paper›PMID 31629738›Full record

ArticleJournal of molecular and cellular cardiology2019

Cardiomyocytes from CCND2-overexpressing human induced-pluripotent stem cells repopulate the myocardial scar in mice: A 6-month study.

Chengming Fan, Vladimir G Fast, Yawen Tang, Meng Zhao, James F Turner, Prasanna Krishnamurthy, Jack M Rogers, Mani T Valarmathi, Jinfu Yang, Wuqiang Zhu and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular and cellular cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Pluripotent stem cell-based approaches for heart repair and the potential of genetic modifications.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Chengming FanDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, USA; Department of Cardiovascular Surgery, the Second Xiangya Hospital, Central South University, Changsha, China.
Vladimir G FastDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, USA.
Yawen TangDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, USA.
Meng ZhaoDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, USA.
James F TurnerDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, USA.
Prasanna KrishnamurthyDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, USA.
Jack M RogersDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, USA.
Mani T ValarmathiDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, USA.
Jinfu YangDepartment of Cardiovascular Surgery, the Second Xiangya Hospital, Central South University, Changsha, China.
Wuqiang ZhuDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, USA. Electronic address: wzhu@uab.edu.
Jianyi ZhangDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, USA. Electronic address: jayzhang@uab.edu.
University of Alabama at Birmingham · USCentral South University · CN

Funding

University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
Integrated Cellular and Tissue Engineering for Ischemic Heart DiseaseU01HL134764 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BURSAC, NENAD, KAMP, TIMOTHY J. · 2016 to 2022
$7.7M
Supplement of HL131017: Myocardial remuscularization by cardiac patch delivery of epicardial FSTL1 and CCND2 overexpressing cardiomyocytesR01HL131017 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SERPOOSHAN, VAHID, ZHANG, JIANYI · 2016 to 2025
$5.8M
Endogenous and exogenous mechanisms that promote myocardial remuscularization in post infarction LV remodelingR01HL114120 · NHLBI · UNIVERSITY OF MINNESOTA · PI ZHANG, JIANYI · 2012 to 2021
$5.6M
Stem Cells For Myocardial Repair: A Large Bore Magnet StudyR01HL095077 · NHLBI · UNIVERSITY OF MINNESOTA · PI ZHANG, JIANYI · 2009 to 2017
$3.8M
Mesenchymal Stem Cell Exosome in Efferocytosis of Apoptotic Cardiomyocytes and Repair after Myocardial IschemiaR01HL138023 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KRISHNAMURTHY, PRASANNA, ZHANG, JIANYI · 2018 to 2021
$2.6M
Myocardial Repair with a Novel Engineered Cardiac Muscle PatchR01HL142627 · NHLBI · MAYO CLINIC ARIZONA · PI ZHU, WUQIANG · 2019 to 2022
$1.7M
Development and Functional Assessment of Cardiovascular Tissue Engineering Therapy (CVTE) T32 Training GrantT32EB023872 · NIBIB · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROGERS, JACK M, ZHANG, JIANYI · 2018 to 2022
$753k
Myocardial Repair with a Novel Engineered Cardiac Muscle PatchR56HL142627 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZHU, WUQIANG · 2018 to 2018
$371k
NHLBI NIH HHS R01 HL095077NHLBI NIH HHS R01 HL114120NHLBI NIH HHS R01 HL131017NHLBI NIH HHS R01 HL138023NHLBI NIH HHS R01 HL142627NHLBI NIH HHS R56 HL142627NHLBI NIH HHS U01 HL134764NIBIB NIH HHS T32 EB023872NIDDK NIH HHS P30 DK079626
6 · The paper itself

Abstract

backgroundCardiomyocytes that have been differentiated from CCND2-overexpressing human induced-pluripotent stem cells (hiPSC-CCND2

methodsNOD/SCID mice were treated with hiPSC-CCND2

resultsSix months later, engrafted cells occupied >50% of the scarred region in CCND2

conclusionsSix months after the transplantation, CCND2-overexpressing hiPSC-CMs proliferated and replaced >50% of the myocardial scar tissue. The large graft hiPSC-CCND2

Indexed as

AnimalsCell ProliferationCicatrixCyclin D2Disease Models, AnimalHumansHypertrophyInduced Pluripotent Stem CellsMyocardial InfarctionMyocardiumMyocytes, CardiacNeovascularization, PhysiologicCCND2 protein, humanCyclin D2Cell cycleHeart failureInduced pluripotent stem cellsMyocardial infarction

Identifiers

PMID31629738
PMCPMC7346870
OpenAlexW2981286440

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.